The cost of mood disorders

Psychiatry

Volumn 5, Issue 4, 2006, Pages 141-145

  Patel, Anita ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

bipolar disorder; cost effectiveness; costs; depression; economic evaluation; mood disorders; psychological therapies; resources; SSRI; tricyclic

Indexed keywords

CARBAMAZEPINE; LITHIUM; MIRTAZAPINE; MOOD STABILIZER; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ARTICLE; BEHAVIOR THERAPY; BIPOLAR DISORDER; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE DELIVERY; HOSPITAL ADMISSION; HUMAN; MAJOR DEPRESSION; MENTAL HEALTH; MENTAL HEALTH CARE; MOOD DISORDER; NATIONAL HEALTH SERVICE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY ADJUSTED LIFE YEAR; SOCIAL WORK; TREATMENT OUTCOME; UNITED KINGDOM; WORLD HEALTH ORGANIZATION;

EID: 33845369880     PISSN: 14761793     EISSN: None     Source Type: Journal    
DOI: 10.1383/psyt.2006.5.4.141     Document Type: Article

References (25)

1. In: Murray C., and Lopez A. (Eds). The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020 (1996), Harvard University Press, Cambridge, MA
2. Lepine J., Gastpar M., Mendlewicz J., and Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12 (1997) 19-29
3. Greener M., and Guest J. Do antidepressants reduce the burden imposed by depression on employers?. CNS Drugs 19 (2005) 253-264
4. Greenberg P., Stiglin L., Finkelstein S., and Berndt E. The economic burden of depression in 1990. J Clin Psychiatry 54 (1993) 405-418
5. Rupp A. The economic consequences of not treating depression. Br J Psychiatry 166 Suppl 27 (1995) 29-33
6. Kind P., and Sorensen J. The costs of depression. Int Clin Psychopharmacol 7 (1993) 191-195
7. Jonsson B., and Bebbington P. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 164 (1994) 665-673
8. Das Gupta R., and Guest J. Annual cost of bipolar disorder to UK society. Br J Psychiatry 180 (2002) 227-233
9. Wyatt R., and Henter I. An economic evaluation of manic-depressive illness, 1991. Soc Psychiatry Psychiatr Epidemiol 30 (1995) 213-219
10. In: Knapp M. (Ed). The economic evaluation of mental health care (1995), Arena, Aldershot
11. Chisholm D., Healey A., and Knapp M. QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol 32 (1997) 68-75
12. Pirraglia P., Rosen A., Hermann R., Olchanski N., and Neumann P. Cost-utility analysis studies of depression management: a systematic review. Am J Psychiatry 161 (2004) 2155-2162
13. Hotopf M., Lewis G., and Norman C. Are SSRIs a cost-effective alternative to tricyclics?. Br J Psychiatry 168 (1996) 404-409
14. Frank L., Revicki D., Sorensen S., and Shih Y. The economics of selective serotonin reuptake inhibitors in depression. A critical review. CNS Drugs 15 (2001) 59-83
15. Woods S., and Baker B. Cost-effectiveness of newer antidepressants. Curr Opin Psychiatry 10 (1997) 95-101
16. Barrett B., Byford S., and Knapp M. Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord 84 (2005) 1-13
17. Keck P., McElroy S., and Bennett J. Health-economic implications of the onset of action of antimanic agents. J Clin Psychiatry 57 Suppl 13 (1996) 13-18
18. Montgomery S., Doyle J., Stern L., and McBurney C. Economic considerations in the prescribing of third-generation antidepressants. Pharmacoeconomics 23 (2005) 477-491
19. Iqbal S., and Prashker M. Pharmacoeconomic evaluation of antidepressants. A critical appraisal of methods. Pharmacoeconomics 23 (2005) 595-606
20. Bower P., Byford S., Barber J., et al. Meta-analysis of data on costs from trials of counselling in primary care: Using individual patient data to overcome sample size limitations in economic analyses. BMJ 326 (2003) 1247-1250
21. National Institute for Clinical Excellence. Depression - management of depression in primary and secondary care. Clinical Guidance 23, December 2004.
22. National Institute for Clinical Excellence. Latest NICE guidance sets new standards for treating depression in children and young people. Press release NICE 2005/022. Issued 28 September 2005.
23. Lam D., McCrone P., Wright K., and Kerr N. Cost-effectiveness of relapse-prevention cognitive therapy for bipolar disorder: 30-month study. Br J Psychiatry 186 (2005) 500-506
24. Rosenbaum J., and Hylan T. Costs of depressive disorders: a review. In: Maj M., and Sartorius N. (Eds). WPA series evidence and experience in psychiatry. Vol. 1. Depressive disorders (1999), Wiley, Chichester (A very comprehensive review of cost and cost-effectiveness issues in depressive disorders.)
25. In: Taylor D., Knapp M., and Kerwin R. (Eds). Pharmacoeconomics in psychiatry (2002), Martin Dunitz, London (A short and highly accessible introductory overview of economic issues in psychopharmacology.)